Minivelle (estradiol transdermal system) Delivers 0.075 mg/day, 8 patches/box, Rx only, Mfd. by: ...

FDA Drug Recall #D-0336-2021 — Class II — April 16, 2021

Recall Summary

Recall Number D-0336-2021
Classification Class II — Moderate risk
Date Initiated April 16, 2021
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Noven Pharmaceuticals Inc
Location Miami, FL
Product Type Drugs
Quantity 12060 cartons

Product Description

Minivelle (estradiol transdermal system) Delivers 0.075 mg/day, 8 patches/box, Rx only, Mfd. by: Noven Pharmaceuticals, Inc. Miami, Florida 33186 Dist. by: Noven Therapeutics, LLC Miami, Florida 33186, NDC 68968-6675-8

Reason for Recall

Defective Delivery System: Out of specification for release rate testing and shear, an attribute related to the adhesive properties of the transdermal patches. As a result, patients could experience patches that do not stick well to the skin.

Distribution Pattern

Nationwide within the United States

Lot / Code Information

Lot #: 88584 Exp. 03/2022

Other Recalls from Noven Pharmaceuticals Inc

Recall # Classification Product Date
D-0055-2025 Class II Xelstrym (dextroamphetamine) transdermal system... Oct 31, 2024
D-0471-2023 Class II Daytrana (methylphenidate transdermal system) C... Mar 10, 2023
D-0472-2023 Class II Daytrana (methylphenidate transdermal system) C... Mar 10, 2023
D-0473-2023 Class II Daytrana (methylphenidate transdermal system) C... Mar 10, 2023
D-0470-2023 Class II Daytrana (methylphenidate transdermal system) C... Mar 10, 2023

Frequently Asked Questions

Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.